Valuation: Gilead Sciences, Inc.

Market Cap 162B 141B 131B 120B 227B 15,433B 230B 1,542B 605B 7,683B 607B 594B 25,762B P/E 2026 *
-46.9x
P/E 2027 * 16.5x
Enterprise Value 171B 149B 139B 127B 240B 16,349B 244B 1,633B 641B 8,139B 643B 629B 27,292B EV / Sales 2026 *
5.63x
EV / Sales 2027 * 5.01x
Free-Float
99.88%
Yield 2026 *
2.53%
Yield 2027 * 2.62%
1 day+0.76%
1 week+0.70%
1 month-0.81%
3 months-1.09%
6 months-8.87%
Current year+6.09%
1 week 128.28
Extreme 128.28
136.26
1 month 127.61
Extreme 127.61
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%+0.70%+15.05%+72.05% 162B
-0.53%-3.95%+50.70%+152.78% 1,024B
+0.21%-2.68%+53.20%+50.87% 618B
-2.51%-3.25%+28.54%+67.99% 443B
+1.30%-0.81%+40.08%+33.81% 349B
+0.04%-1.43%+33.94%+42.24% 297B
-4.93%-6.71%+7.97%+10.31% 264B
+0.21%-5.93%-1.87%-42.77% 209B
-0.64%+2.43%+29.74%+67.16% 208B
+0.40%+1.92%+6.47%-29.25% 143B
Average +0.01%-1.02%+26.38%+42.52% 371.63B
Weighted average by Cap. +0.36%-2.01%+35.73%+69.34%

Financials

2026 *2027 *
Net sales 30.42B 26.45B 24.62B 22.6B 42.68B 2,904B 43.34B 290B 114B 1,446B 114B 112B 4,848B 32.3B 28.08B 26.13B 23.99B 45.31B 3,083B 46.01B 308B 121B 1,535B 121B 119B 5,147B
Net income -3.39B -2.95B -2.74B -2.52B -4.76B -324B -4.83B -32.34B -12.69B -161B -12.73B -12.45B -540B 9.78B 8.5B 7.91B 7.26B 13.72B 934B 13.93B 93.27B 36.61B 465B 36.73B 35.92B 1,558B
Net Debt 9.6B 8.34B 7.77B 7.13B 13.46B 916B 13.67B 91.54B 35.93B 456B 36.04B 35.25B 1,529B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-31 $130.21 -0.82% 6,531,645
26-07-30 $131.28 -1.09% 6,726,143
26-07-29 $132.73 -1.18% 7,766,370
26-07-28 $134.32 +2.91% 6,947,167
26-07-27 $130.52 +0.94% 4,953,801
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
130.21USD
Average target price
157.15USD
Spread / Average Target
+20.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock